United Cannabis (CNABQ) 10-Q 9 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 09, 2018
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1,436,161
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		75,860,641
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 275,233	$ 825,645
Accounts receivable, net	80,249
Inventory	2,662,451	43,200
Due from related parties	103,402
Other current assets	49,360	23,028
Total current assets	3,170,695	891,873
Construction in progress	961,527	832,697
Property, plant and equipment, net	1,922,496	199,821
Granted patents, net	134,301	139,638
Intangible assets	264,769	170,519
Other assets	71,576
Goodwill	4,838,603	4,838,603
Total assets	11,363,967	7,073,151
Current liabilities:
Accounts payable	582,117	371,711
Accrued expenses	34,413	10,184
Installment loan payable	64,278	46,667
Deferred revenue	68,750	180,000
Accrued wages payable to officers and directors		310,401
Notes payable for advances from and prior wages payable to officers and directors	1,125,892	261,348
Convertible notes payable, net	283,861
Arbitration and litigation reserve	650,000
Total current liabilities	2,809,311	1,180,311
Long term liabilities:
Deferred revenue, net of current portion		23,750
Total liabilities	2,809,311	1,204,061
COMMITMENTS AND CONTINGENCIES - Note 19
STOCKHOLDERS' EQUITY
Preferred stock, 10,000,000 shares authorized; 2,000 Series A shares outstanding at September 30, 2018 and December 31, 2017, respectively	2,200	2,200
Common stock, 100,000,000 shares authorized; 74,180,490 and 62,862,066 shares outstanding as of September 30, 2018 and December 31, 2017, respectively	44,943,406	21,186,888
Accumulated deficit	(36,218,959)	(15,269,845)
Total equity (deficit) attributable to stockholders of the Company	8,726,647	5,919,243
Non-controlling interest (deficit)	(171,991)	(50,153)
Total stockholders' equity	8,554,656	5,869,090
Total liabilities and stockholders' equity	$ 11,363,967	$ 7,073,151

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	74,180,490	62,862,066
Series A Preferred Stock [Member]
Preferred stock, shares outstanding	2,000	2,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues
Product revenues	$ 2,099,591	$ 12,627	$ 4,026,298	$ 142,685
Licensing fees	32,712	45,000	135,000	135,000
Revenues, affiliate		45,033	99,103	178,785
Total revenues	2,132,303	102,660	4,260,401	456,470
Cost of revenues	(1,567,031)	(26,226)	(3,079,442)	(238,227)
Gross profit	565,272	76,434	1,180,959	218,243
Operating expenses
Marketing, advertising and new business development	143,083	39,728	170,104	132,493
Research and development	257,658	40,611	735,883	90,006
Legal, accounting, consulting and public reporting	287,959	181,052	930,784	637,252
General and administrative	1,152,822	461,990	3,218,804	1,020,041
Share-based expense for stock options granted to officers, directors and employees	179,018		14,689,497	1,624,000
Total operating expenses	2,020,540	723,381	19,745,072	3,503,792
Loss from operations	(1,455,268)	(646,947)	(18,564,113)	(3,285,549)
Other income and costs and expenses
Loss on extinguishment of debt				(267,567)
Interest expense	(121,162)	(6,759)	(172,265)	(54,432)
Loss on issuance of common stock	(939,229)		(1,867,830)
Loss on conversion of convertible note	(466,744)		(466,744)
Loss on settlement of dispute				(122,139)
Loss before provision for taxes on income	(2,982,403)	(653,706)	(21,070,952)	(3,729,687)
Provision for taxes on income
Net Income (Loss)	(2,982,403)	(653,706)	(21,070,952)	(3,729,687)
Loss attributable to non-controlling interests	37,538	80,914	121,837	242,146
Net (Loss) attributable to common shareholders	$ (2,944,865)	$ (572,792)	$ (20,949,115)	$ (3,487,541)
Basic loss per common share	$ (0.04)	$ (0.01)	$ (0.31)	$ (0.07)
Basic and fully diluted weighted average number of shares outstanding	70,818,495	44,925,837	66,626,106	54,170,003

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net loss	$ (21,070,952)	$ (3,729,687)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount	22,042	34,453
Depreciation and amortization	264,445	26,299
Share-based compensation	15,238,156	2,117,302
Loss on issuance of common stock	1,867,830
Loss on conversion of convertible note	466,744
Loss on extinguishment of debt and repurchase of warrants		248,892
Loss on settlement of dispute		122,139
Changes in operating assets and liabilities:
Accounts receivable	(80,249)	(1,216)
Due from related parties	(103,402)	(10,508)
Other current assets	(26,332)
Accounts payable and accrued expenses	326,610	23,271
Deferred revenue	(135,000)	(135,000)
Accrued wages payable to officers and directors		302,889
Net cash used in operating activities	(3,230,108)	(1,001,166)
Investing activities:
Cash acquired upon acquisition of subsidiary		347,307
Purchase of inventory	(2,033,898)	(36,098)
Purchase of equipment and improvements to cultivation facilities	(2,619,251)	(261,560)
Purchase of intangible assets	(94,250)	(125,858)
Deposits and return of deposit	(71,576)	(32,500)
Cash portion of settlement of dispute		(20,000)
Net cash used in investing activities	(4,818,975)	(128,709)
Financing activities:
Proceeds from issuance of common stock - equity financing line	5,390,049	1,380,204
Proceeds from convertible notes	845,000
Proceeds from proposed joint venture that was never formed - litigation reserve	650,000
Proceeds from advances from officers and directors	554,143	254,943
Proceeds from sale of common stock	118,583	64,804
Repayment of convertible debt and notes payable		(35,000)
Payments on installment loans	(59,104)
Net cash provided by financing activities	7,498,671	1,664,951
Net increase (decrease) in cash	(550,412)	535,076
Cash, beginning of period	825,645	112,621
Cash, end of period	275,233	647,697
Supplemental schedule of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Acquisition from and leaseback to of equipment to related party		99,200
Common shares issued in the acquisition of Prana Therapeutics, Inc.		4,870,500
Conversion to notes payable for advance from officer and directors	310,401
Exercise of stock option for 1,000,000 of common stock in exchange for notes payable to an officer and director		$ 200,000

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	9 Months Ended
	Sep. 30, 2017shares
Statement of Cash Flows [Abstract]
Notes payable in exchange for shares of common stock	1,000,000

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue with over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“PTI”) by exchanging 5,730,000 shares of common stock of the Company for 5,730,000 shares of the common stock of PTI. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB Market on July 14, 2017, including the cost to purchase 400,000 shares of PTI common stock for $200,000. PTI is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase PTI, because of the successful indication of the effectiveness of PTI’s Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, and (iii)the potential shrinkage of cancerous tumors. On August 3, 2018, PTI received notice that its licensed flagship product, EDP™, received approval on an Investigational New Drug application from the FDA for a clinical investigation for breast cancer. The clinical investigation will include a dose escalation, safety, tolerability, pharmacokinetic, and efficacy trial. Phase 1 will test the potential toxicity of EDP™ at two targeted dosages and measures safety levels, side effects, optimal dosage, and formulation. Phase 2 will focus on whether or not EDP™ passes efficacy evaluations by reducing side effects of chemotherapy in patients. Recently, we elected to focus a significant portion of our assets, human resources and financial capital on the manufacturing and selling of a variety of cannabidiol centric products derived from industrial hemp plants. We constructed a state-of-the-art extraction facility; and, hired and trained specialized extraction personnel and laboratory technicians that enable us to convert components of industrial hemp flower to finished CBD products. In order to help provide a consistent supply of industrial hemp flower for our extraction facility, we purchased farming equipment and leased hundreds of acres of farm land on which we are growing a crop of industrial hemp. It is our intent to grow at least one crop of industrial hemp plants per calendar year and to harvest a sufficient amount of industrial hemp flower from our crop to supply our extraction facility on a vertically integrated basis. As of September 30, 2018, we have expended approximately $2,800,000 on facilities, farm equipment and crop planting and cultivation, as a result of electing to vertically integrate the hemp centric portion of our business. Government Regulation

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and its assets and liabilities are included in the consolidated balance sheets at December 31, 2017, and their results of operations are included in the consolidated financial statements for the period of September 30, 2017, which is the nearest quarter end to the purchase date, through December 31, 2017. Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at September 30, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the nine-month period ended September 30, 2018 and the year ended December 31, 2017. Cash and Cash Equivalents Accounts Receivable, Net Inventory – Property, Plant and Equipment, net Granted Patents, Net – Intangible Assets – Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of September 30, 2018 or December 31, 2017. Goodwill fl Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers. We have licensed Prana Hemp Prana Hemp Prana Hemp Prana Hemp Prana Hemp Revenue from Contracts with Customers. Cost of Revenues Research and Development Expenses General and Administrative Expenses Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017 or the nine months ended September 30, 2018. Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Warrants to purchase common stock 1,271,530 1,424,112 1,284,031 1,424,112 Stock options 25,080,000 6,580,000 25,080,000 6,580,000 26,351,530 8,004,112 26,364,031 8,004,112 Other Comprehensive Income (Loss) Concentration of Credit Risk Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures. In June 2018, the FASB issued updated guidance on accounting for nonemployee share-based award payments granted to acquire goods and services to be used or consumed in the grantor’s own operations. This guidance does not apply in the case that the share-based payment was made to provide financing to the issuer, or in the case that the awards are made in conjunction with selling goods and services to customer under a contract accounted for under Topic 606 – Revenue from Contracts with Customers. The stated objectives of this update are part of FASB’s simplification Initiative, and provisions affecting publicly held companies include simplifying (1) the method that nonemployee share-based awards are measured; (2) the method used to arrive at the measurement date; (3) accounting for share-based awards with performance conditions; and (4) the classification reassessment of share-base awards in certain situations. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures. Reclassification

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2018
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine-months ended September 30, 2018, we incurred losses of $21,070,952, used cash of $3,230,108 in our operating activities and had an accumulated deficit of $36,218,959 at September 30, 2018. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

DUE FROM RELATED PARTIES

DUE FROM RELATED PARTIES	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
DUE FROM RELATED PARTIES	NOTE 4 – DUE FROM RELATED PARTIES Amounts due from related from related parties include the following: September 30, December 31, Advesa, Inc. $ 44,402 $ — NutriMed, LLC 59,000 — $ 103,402 $ — In the normal course of business, we make non-interest-bearing advances to Advesa, Inc. (“Advesa’), which is controlled by one of our officers and directors, and we receive licensing fees from the sale of products licensed to Advesa by the Company. In the normal course of business, we sell products to NutriMed, LLC, which is controlled by two of our officers and directors. The products that we sell to NutriMed, LLC are at a price equivalent to the whole sale price that we charged to unrelated, third party distributors.

OPERATING LEASES

OPERATING LEASES	9 Months Ended
	Sep. 30, 2018
Leases [Abstract]
OPERATING LEASES	NOTE 5 – OPERATING LEASES Administrative Offices and Industrial Hemp Laboratory – Golden, Colorado Effective August 1, 2017, we entered into a triple net lease for approximately 9,882 square feet of commercial space in Golden, Colorado in which our administrative offices and industrial hemp laboratory are located. The lease expires on July 31, 2020 and has no option for renewal. Basic rent is $3,302, $3,500 and $3,800 per month through, July 31, 2018, 2019 and 2020, respectively, plus we are responsible for all utilities. Extraction and Cultivation Facility – Weldona, Colorado Effective October 1, 2017, we entered into a triple net lease for approximately 40,000 square feet of industrial space located on five (5) acres of land in Weldona, Colorado that we use as our industrial hemp extraction facility and industrial hemp cultivation center. The lease expires on September 31, 2018, with an annual option to renew the lease on an annual basis, until September 30, 2022. The rent is $7,500 per month throughout the term of the lease, plus we are responsible for all utilities. Extraction and Cultivation Facility – Mead, Colorado Effective September 1, 2018, we entered into a triple net lease for approximately 14,300 square feet of industrial space located in Mead, Colorado that we use as an industrial hemp extraction facility. The term of the lease expires on August 31, 2023. The rent is $12,596 per month throughout the term of the lease, plus we are responsible for all utilities. Extraction and Cultivation Facility Jamaica Our fifty percent (50%) owned subsidiary Cannabinoid Research & Development Company Limited (“CRD”) leases approximately 28 acres of land upon which their cultivation and extraction facility is located near Kingston, Jamaica. The land is leased for $1 per year from the father of one of the directors and members of CRD. Future minimum payments for these leases are: For the twelve Months Ending September 30, 2019 2020 2021 2022 2023 $283,753 $279,150 $241,153 $241,153 $158,365

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
INVENTORY	NOTE 6 – INVENTORY At September 30, 2018 and December 31, 2017, our inventory is, as follows: September 30, December 31, 2018 2017 Raw materials $ 2,511,396 $ 15,000 Work-in-process 49,735 — Finished goods 101,320 28,200 $ 2,662,451 $ 43,200 We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of revenue sold. There have been no such write-downs during the nine-month period ended September 30, 2018 and 2017.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT, NET September 30, December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Mead, Colorado extraction facility Equipment 775,828 — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 961,527 $ 832,697 Extraction facility, laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,151,263 — Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements 209,796 2,000 Transportation equipment 234,964 81,667 Remote laboratory equipment 99,220 99,220 Farm Equipment 436,492 — $ 2,220,961 239,206 Accumulated amortization and depreciation (298,465 ) (39,385 ) $ 1,922,496 $ 199,821 The amount of depreciation and amortization expense for the three and nine months ended September 30, 2018 is $106,567 and $259,108, respectively. The amount of depreciation and amortization expense for the three and nine months ended September 30, 2017 was $18,449 and $25,106, respectively.

PURCHASE OF PRANA THERAPUETICS,

PURCHASE OF PRANA THERAPUETICS, INC.	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
PURCHASE OF PRANA THERAPUETICS, INC.	NOTE 8 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“PTI”), for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid PTI $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to PTI on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. On July 14, 2017, we completed the acquisition of PTI in an exchange of 5,730,000 shares of our common stock for 5,730,000 shares of the common stock of PTI. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB Market on July 14, 2017, including the cost to purchase 400,000 shares of PTI for $200,000. The purchase price for PTI was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: September 30, 2018 Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

GRANTED PATENTS, NET

GRANTED PATENTS, NET	9 Months Ended
	Sep. 30, 2018
Granted Patent [Abstract]
GRANTED PATENTS, NET	NOTE 9 – GRANTED PATENTS, NET On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary composition of matter in liquid formulations, based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for the Company’s proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost on a straight-line basis over a 15-year period. Amortization expense of the Patent is $1,779 and $5,337 for the three-months and nine-months ended September 30, 2018 and $0.0 for both the three-months and nine-months period ended September 30, 2017, respectively and accumulated amortization is $8,016 and $2,679 at September 30, 2018 and December 31, 2017, respectively.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 10 – INTANGIBLE ASSETS Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

INSTALLMENT LOANS PAYABLE

INSTALLMENT LOANS PAYABLE	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
INSTALLMENT LOANS PAYABLE	NOTE 11 – INSTALLMENT LOANS PAYABLE Installment loans payable consist of a 48-month installment loan for the purchase of a truck that is used at our extraction facility, as well as a 36-month installment loan for the purchase an SUV used for Company purposes. The outstanding balance on the 48-month installment loan was $0 and $46,667 at September 30, 2018, and December 31, 2017, respectively. The terms of the 48-month installment loan specify monthly payments of $955; however, we are making payments of $6,955 per month to pay the loan off in a nine-month period. As a result of our intentions to pay the loan off in nine months, the entire balance of the 48-month installment loan has been classified as a current liability; this installment loan was fully paid at September 30, 2018. The outstanding balance on the 36-month installment loan was $68,750 and $46,667 at September 30, 2018, and December 31, 2017, respectively. The terms of the 36-month installment loan specify monthly payments of $2,160, however, we are making payments of $6,500 per month to pay the loan off within a one-year period. As a result of our intentions to pay off the loan within one year, the entire balance of the 36-month installment loan has been classified as a current liability.

DEFERRED REVENUE

DEFERRED REVENUE	9 Months Ended
	Sep. 30, 2018
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 12 – DEFERRED REVENUE Our deferred revenue consists of: September 30, December 31, 2018 2017 Current portion $ 68,750 $ 180,000 Long term portion — 23,750 Deferred revenue $ 68,750 $ 203,750 On September 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD (“WMD”) in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three-year estimate of the service period involved. Based on recent discussions with WMD, we now expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four-year period from January 1, 2015 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month. We recognized $90,000 of revenue applicable to this arrangement in each of the nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018, we expect to recognize the remaining $68,750 WMD deferred revenue during the next twelve months, and accordingly, we have classified the $68,750 as a current liability on our consolidated balance sheets.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2018
CONVERTIBLE NOTE PAYABLE [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 13 – CONVERTIBLE NOTES PAYABLE During the nine months ended September 30, 2018, we issued convertible promissory notes to an unaffiliated third party. The net proceeds from these notes were used for general working capital purposes. The debt discounts and deferred financing costs on the convertible promissory notes are amortized on a straight-line basis, which approximates the effective interest rate method, over the term of the note, and this amortization is included in interest expense in our consolidated statements of operations. On September 29, 2018, we converted a $600,000 convertible note through the issuance to the lender of 1,956,522 shares of our common stock. We recognized a loss on the conversion of the $600,000 convertible note in the amount of $496,023 for the three months and nine months ended September 30, 2018. The following table summarizes our convertible promissory notes outstanding as of September 30, 2018 and December 31, 2017: Issue Holder Security Maturity Interest Base September 30, December 31, 6-04-18 Tangiers Global Unsecured 12-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holder’s election to convert $ 288,750 $ — Less unamortized Discount (4,889 ) — $ 283,861 $ — During the three months and nine months ended September 30, 2018, we recognized $22,042 and $38,861, respectively, of amortization of deferred financing costs, respectively. This amount is included in interest expense in our consolidated statements of operations.

NOTES PAYABLE FOR ADVANCES FROM

NOTES PAYABLE FOR ADVANCES FROM AND PRIOR WAGES PAYABLE TO OFFICERS AND DIRECTORS	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE FOR ADVANCES FROM AND PRIOR WAGES PAYABLE TO OFFICERS AND DIRECTORS	NOTE 14 – NOTES PAYABLE FOR ADVANCES FROM AND PRIOR WAGES PAYABLE TO OFFICERS AND DIRECTORS Notes payable, including accrued interest payable, to and advance from officers and directors consisted of the following: September 30, December 31, 2018 2017 Notes payable to Earnie Blackmon, an officer and director $ 816,195 $ 246,459 Note payable to Tony Verzura, an officer and director 159,833 14,889 Note payable to Chadwick Ruby, an officer and director 149,864 — $ 1,125,892 $ 261,348 On April 6, 2016, we borrowed $25,000 from Ernest Blackmon and $25,000 from Tony Verzura and used the proceeds to repay principal and interest applicable on our $102,000 convertible promissory note dated October 12, 2015, to JSJ Investments Inc. The loans, together with interest at 12% per year, are payable on December 30, 2016. We may prepay the loans at any time. If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%. As of December 31, 2016, the loans were not repaid, when they were due, per the terms of the notes, and thus, the principal balance of the notes at that date was increased to $57,500 in the aggregate, with the addition to the principal balance charged to interest expense. Historically, Messrs. Blackmon, Verzura and Ruby, who are officers and directors of the Company, have paid obligations and expenses on behalf of the Company from their own individual, personal funds. Such payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors. During the nine months ended September 30, 2018, Mr. Blackmon, the Chairman, Chief Executive Officer and President of the Company paid $554,143, net of reimbursements, of obligations and expenses of the Company from his own personal funds. These payments have been recorded in the consolidated balance sheets as a component of Notes payable to and advances from officers and directors. On July 1, 2018, we elected to convert all accrued and unpaid wages owed to Messrs. Blackmon, Verzura, and Ruby in the aggregate amount of $310,408 as notes payable to them. Thus, $310,408 is classified as Notes Payable For Advances from And Prior Wages Payable to Officers and Directors on the consolidated balance sheet of the Company at September 30, 2018. Interest on the notes is at a rate of 15% for the principal amount due Mr. Blackmon, and at a rate of 12.5% for on the principal amount owed Messrs. Verzura and Ruby.

ARBITRATION AND LITIGATION RESE

ARBITRATION AND LITIGATION RESERVE	9 Months Ended
	Sep. 30, 2018
Loss Contingency [Abstract]
ARBITRATION AND LITIGATION RESERVE	NOTE 15 – ARBITRATION AND LITIGATION RESERVE On May 8, 2018, H2, LLC (“H2”) and the Company executed a letter of intent formalizing their intent to enter into a joint venture. The parties subsequently made monetary advances in anticipation of formalizing the joint venture through a definitive agreement. However, the joint venture was never formalized, and the letter of intent was terminated pursuant to its terms. Under the terms of the provisions in the letter of intent that survived its termination, the Company has the option to either provide H2 with 25% of the industrial hemp seeds purchased with $650,000 advanced by H2, or to refund the $650,000 advanced by H2. Pursuant to another provision in the letter of intent that survived termination, disputes are to be resolved via arbitration in Denver, Colorado. On August 10, 2018, H2 filed a lawsuit in the state of California naming the Company, as well as, naming Earnest Blackmon, our Chairman of the Board and Chief Executive Officer, and John Walsh, our Treasurer and Chief Accounting Officer. The lawsuit asserts various claims, including rescission of any purported contract or joint venture and asks for $16,500,000 in damages. Our counsel and Management believe the suit is without merit, and we will vigorously defend against the lawsuit. We filed with the court a motion to compel arbitration, and we believe the court will stay the litigation and compel arbitration.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 16 – STOCKHOLDERS’ EQUITY Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A preferred stock for $2,200 to certain of our officers and to each director. Warrants: The following table summarizes our warrants outstanding as of September 30, 2018 and December 31, 2017: September 30, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 75,006 0.95 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,284,031 $ 0.31 1,209,025 $ 0.21 Warrants exercisable, end of period 1,284,031 $ 0.31 1,209,025 $ 0.21 The weighted-average remaining contractual life for warrants outstanding and exercisable at September 30, 2018, is 3.63 years, and the aggregate intrinsic value of warrants outstanding and exercisable at September 30, 2018 is $0. 666,667 warrants issued during the year ended December 31, 2017 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 75,006 warrants issued during the nine months ended September 30, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % Stock Options On February 28, 2018, we awarded 6,000,000 stock options to various employees under our 2017 Stock Incentive Plan. Of these options, 5,125,000 were fully vested at the time of grant with the remaining 875,000 vesting quarterly through December 31, 2019. The awarded options give the option holder the right to purchase shares of our common stock at $1.08 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % The total grant-date fair value of these options was approximately $6,146,000. Stock-based compensation expense related to these stock options included in operating expenses for the nine months ended September 30, 2018 was approximately $5,584,498. On June 29, 2018, we awarded 14,195,000 stock options to various employees under our 2018 Stock Incentive Plan. Of these options, 13,250,000 were fully vested at the time of grant with the remaining 945,000 vesting quarterly through July 1, 2022. The awarded options give the option holder the right to purchase shares of our common stock at $0.705 per share during the ten-year term of the option. We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.71 Exercise price $ 0.95 Risk free interest rate 2.68 - 2.79 % Expected term (years) 5 Expected volatility 210% - 214 % Expected dividends 0 % The total grant-date fair value of these options was approximately $9,711,400. Stock-based compensation expense related to these stock options included in operating expenses for the nine months ended September 30, 2018 was approximately $9,104,999. The following table summarizes our stock options outstanding as of both September 30, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 9.9 0.64 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,637,500 8.7 $ 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 20,195,000 9.5 $ 0.83 Exercised — Expired — Stock options outstanding at September 30, 2018 26,832,500 9.4 $ 0.75 Stock options exercisable at September 30, 2018 25,080,000 9.5 $ 0.74 The total price to exercise all outstanding stock options is $10,259,575. The weighted-average remaining contractual life for stock options outstanding and exercisable at September 30, 2018 is 9.2 years, and the aggregate intrinsic value of options outstanding and exercisable at September 30, 2018 is $0.75. On July 25, 2018, we repriced the exercise price per share from $1.08 to $0.58 per share for the stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and repriced the exercise price per share from $0.705 to $0.58 per share for the stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the three and nine months ended September 30, 2018 was necessary as a result of the repricing of the stock options. On August 17, 2018, we repriced the exercise price per share (i) from $0.70 to $0.43 for per share for stock options to purchase 600,000 shares of our common stock that were granted on January 1, 2015 (ii) from 0.56 to $0.43 for per share for stock options to purchase 2,900,000 shares of our common stock that were granted on January 12, 2016 (iii) from $0.92 to $0.43 for 57,500 per share for stock options to purchase 57,500 shares of our common stock that were granted on July 27, 2017 (iv) from $0.875 to $0.43 per share for stock options to purchase 1,000,000 shares of our common stock that were granted on December 8, 2017 (v) from $.058 to $0.43 per share for stock options to purchase 6,000,000 shares of our common stock that were granted on March 28, 2018 and (vi) from $0.58 to $0.43 per share for stock options to purchase 14,195,000 of our common stock that were granted on June 29, 2018. No adjustment to shared-based compensation in the consolidated financial statements for the three and nine months ended September 30, 2018 was necessary as a result of the repricing of the stock options.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 17 – SHARE-BASED COMPENSATION We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, research and development expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the nine months ended September 30, 2018 and 2017, Share-based compensation expense for the three months and nine months ended September 30, 2018 and 2017 is, as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Options granted to officers, directors and employees $ 179,018 $ — $ 14,689,497 $ 1,812,456 Common stock issued for accounts payable and accrued expenses — 22,949 — 117,509 Options granted for services — — — — Warrants and options issued for consulting services 25,002 — 76,322 16,379 Common stock issued for services 77,164 68,984 238,637 170,958 Common stock issued as compensation to employees 42,600 — 233,700 — $ 323,784 $ 91,933 $ 15,238,156 $ 2,117,302 The stock options issued to officers and directors were issued under the 2018 Stock Incentive Plan, and such options were fully vested at the date of grant.

SIGNIFICANT CUSTOMER INFORMATIO

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	9 Months Ended
	Sep. 30, 2018
Risks and Uncertainties [Abstract]
SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY	NOTE 18 – SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Nine Months Ended September 30, 2018 2017 Customer A 14 % 82 % Customer B 14 % 17 % Customer C 9 % 1 % Percentage of Accounts Receivable: As of September 30, 2018 2017 Customer D 81 % 0 % Customer E 18 % 0 % Customer F 1 % 0 % The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Nine Months Ended September 30, 2018 2017 Vendor A 4 % 13 % Vendor B 2 % 6 % Vendor C 2 % 4 % Percentage of Accounts Payable: As of September 30, 2018 2017 Vendor D 21 % 72 % Vendor E 12 % 13 % Vendor F 10 % 6 %

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 19 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments Financing Commitment On August 3, 2018, our 95% owned subsidiary, Prana Therapeutics, Inc. (“PTI”) received approval of an Investigational New Drug (“IND”) application from the Department of Health and Human Services’ Food and Drug Administration for a clinical investigation for breast cancer of PTI’s licensed flagship product, Epidiferphane™ (EDP™). We have committed to spend approximately $300,000 to fund phase I and phase II clinical trials in connection with the IND approval. On January 19, 2018, we entered into an equity line of credit agreement with Tangiers Global, LLC (“Tangiers”). Under the equity line agreement, Tangiers has agreed to provide the Company with up to $10,000,000 of funding through the purchase of shares of the Company’s common stock. During the term of the agreement, the Company may deliver a put notice to Tangiers, which will specify the number of shares which the Company will sell to Tangiers. The maximum amount that the Company shall be entitled to put to Tangiers per any applicable put notice is that number of shares of our common stock up to or equal to 400% of the average of the daily trading volume of our common stock for the eight consecutive trading days immediately prior to the date of the applicable put notice. The minimum amount the Company can draw down at any one time is $5,000, and the maximum amount the Company can draw down at any one time is $1,000,000, as determined by multiplying the put amount by the average daily volume weighted average prices of our common stock for the ten (10) trading days immediately prior to the applicable put notice. A closing will occur on the date which is no earlier than five (5) trading days following, and no later than seven (7) trading days following, the applicable put notice. On each closing date, the Company will sell, and Tangiers will purchase, the shares of the Company’s common stock specified in the put notice. The amount to be paid by Tangiers on a particular closing date will be determined by multiplying the purchase price by the number of shares specified in the put notice. The purchase price is 85% of the average the two lowest volume weighted average trading prices of the Company’s common stock during the pricing period applicable to the put notice. The pricing period, with respect to a particular put notice, is five consecutive trading days including, and immediately following, the delivery of a put notice to Tangiers. The Company may submit a put notice once every eight trading days, provided the closing of the previous transaction has taken place. The Company is under no obligation to submit any put notices. As of September 30, 2018, the Company has delivered eight (8) put notices to Tangiers, and, has received $5,390,049, under the terms of the equity line of credit agreement from the sale of 8,655,711 shares of the Company’s common stock to Tangiers. Clinical Trial Agreement Under the terms of an agreement dated November 11, 2017, we committed to pay the costs to perform clinical trials with The University of the West Indies through the Topical Metabolism Research Unit of the Caribbean Institute for Health Research located in Kingston, Jamaica, initially scheduled as follows: · An instalment of $50,000 upon both the approval of specific protocol by the Ethics Committee of the Institutional Review Board of the Ministry of Health, Jamaica, and the execution of the clinical trial agreement, the payment of which has been charged to the cost of research and development in the Statement of Operations for the three months and nine months ended September 30, 2018, · An instalment of $51,182 upon the enrollment of the 12 th · An instalment of $51,182 after all twelve patients go through the washout period determined in the specific protocol and return for a second dose, and · An instalment of $51,182 upon completion of the clinical trial. Additionally, we have agreed to reimburse The University of the West Indies for care and treatment of patients suffering adverse reactions or injury sustained by a patient, as a direct result of the clinical trial. Research Laboratory In October 2017, our 95% owned subsidiary, Prana Therapeutics, Inc (“PTI”), entered into a research agreement with the University of Florida Trustees (“UFT”). Under the terms of the research agreement PTI committed to pay UFT $303,544 in four (4) installments, of which $75,886 is owed as of September 30, 2018. Industrial Hemp Crop Under Cultivation We entered into a farm lease for acreage on which the Company is growing an industrial hemp crop. The rent for the acreage under the terms of the farm lease is in an amount per acre predicated upon the total weight in pounds of industrial hemp flower harvested at a rate of $2 per pound (dry weight, after thrashing to remove seeds), with a minimum of $1,000 per acre. The rent is payable in three (3) installments; (i) one third on November 15, 2018, (ii) one third on December 31, 2018 and (iii) the remainder of all rents is payable on February 15, 2019. Industrial Hemp Crop Under Cultivation – Transaction with and Commitment to a Related Party Approximately 30% of the farm acreage, on which we are growing our industrial hemp crop, is contractually controlled by a joint venture, NEC Agri Services, LLC (“NEC”). Our Principal Financial Officer is one of the managing members and owners of NEC. In exchange for supplying the farm acreage along with certain farm equipment, infrastructure and our lead farmer and farm management, the Company agreed to pay NEC a stipulated dollar amount per weight in pounds of industrial hemp flower harvested on the NEC farm acreage (dry weight after thrashing for the removal of seeds), reduced by a ratable allocation per acre of total farming costs for the industrial hemp crop under cultivation. We believe the stipulated dollar amount per weight in pounds is commensurate to the fair market value that we could have received from an independent farmer and land owner. Acquisition of Hemp Biomass We entered into an agreement on October 2, 2018 for the purchase of industrial hemp biomass at a total purchase price of $1,152,000 to be remitted to the supplier in varying amounts through December 5, 2018.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – SUBSEQUENT EVENTS Subsequent to September 30, 2018, we received $701,400 under the terms of the equity line of credit agreement with Tangiers Global, LLC from the sale of 1,630,051 shares of our common stock to Tangiers. On November 8, 2018, we entered into a $1.500,000 convertible note (“Note”) with Tangiers Global, LLC (“Holder”). We may make draws under the terms of the Note at our discretion, and any principal and interest on draws made under the terms of the Note are due and payable on May 7, 2019. Upon any default, the Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during a 15-day period prior to Holder’s election to convert. In accordance with ASC 855-10 we have analyzed our operations subsequent to September 30, 2018 to the date these consolidated financial statements were issued, and have determined that, other than as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. PTI was purchased on July 14, 2017, and its assets and liabilities are included in the consolidated balance sheets at December 31, 2017, and their results of operations are included in the consolidated financial statements for the period of September 30, 2017, which is the nearest quarter end to the purchase date, through December 31, 2017.
Use of Estimates	Use of Estimates We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at September 30, 2018, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the nine-month period ended September 30, 2018 and the year ended December 31, 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable, Net	Accounts Receivable, Net
Inventory	Inventory –
Property, Plant and Equipment, net	Property, Plant and Equipment, net
Granted Patents. Net	Granted Patents, Net –
Intangible Assets	Intangible Assets –
Long-Lived Assets Impairment Assessment	Long-Lived Assets Impairment Assessment We have not recorded any impairment charges related to long-lived assets as of September 30, 2018 or December 31, 2017.
Goodwill	Goodwill fl
Purchase Price Allocation	Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures
Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Revenue from Contracts with Customers. We have licensed Prana Hemp Prana Hemp Prana Hemp Prana Hemp Prana Hemp Revenue from Contracts with Customers.
Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses
General and Administrative Expenses	General and Administrative Expenses
Stock-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no impact on our income taxes for the year ended year-ended December 31, 2017 or the nine months ended September 30, 2018.
Commitments and Contingencies	Commitments and Contingencies – Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Loss Per Share	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Warrants to purchase common stock 1,271,530 1,424,112 1,284,031 1,424,112 Stock options 25,080,000 6,580,000 25,080,000 6,580,000 26,351,530 8,004,112 26,364,031 8,004,112
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Concentration of Credit Risk	Concentration of Credit Risk
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures. In June 2018, the FASB issued updated guidance on accounting for nonemployee share-based award payments granted to acquire goods and services to be used or consumed in the grantor’s own operations. This guidance does not apply in the case that the share-based payment was made to provide financing to the issuer, or in the case that the awards are made in conjunction with selling goods and services to customer under a contract accounted for under Topic 606 – Revenue from Contracts with Customers. The stated objectives of this update are part of FASB’s simplification Initiative, and provisions affecting publicly held companies include simplifying (1) the method that nonemployee share-based awards are measured; (2) the method used to arrive at the measurement date; (3) accounting for share-based awards with performance conditions; and (4) the classification reassessment of share-base awards in certain situations. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.
Reclassification	Reclassification

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Warrants to purchase common stock 1,271,530 1,424,112 1,284,031 1,424,112 Stock options 25,080,000 6,580,000 25,080,000 6,580,000 26,351,530 8,004,112 26,364,031 8,004,112

DUE FROM RELATED PARTIES (Table

DUE FROM RELATED PARTIES (Table)	9 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Schedule of Amounts Due From Related Parties	Amounts due from related from related parties include the following: September 30, December 31, Advesa, Inc. $ 44,402 $ — NutriMed, LLC 59,000 — $ 103,402 $ —

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	9 Months Ended
	Sep. 30, 2018
Leases [Abstract]
Schedule of Operating Leases	Future minimum payments for these leases are: For the twelve Months Ending September 30, 2019 2020 2021 2022 2023 $283,753 $279,150 $241,153 $241,153 $158,365

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	At September 30, 2018 and December 31, 2017, our inventory is, as follows: September 30, December 31, 2018 2017 Raw materials $ 2,511,396 $ 15,000 Work-in-process 49,735 — Finished goods 101,320 28,200 $ 2,662,451 $ 43,200

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment, Net [Abstract]
Schedule of Property and Equipment	September 30, December 31, 2018 2017 Cost of construction in process - extraction facility Weldona, Colorado extraction facility: Equipment $ — $ 647,947 Mead, Colorado extraction facility Equipment 775,828 — Jamaica cultivation and extraction facility: Leasehold improvements - laboratory 75,000 75,000 Leasehold improvements - cultivation 110,699 109,750 $ 961,527 $ 832,697 Extraction facility, laboratory equipment, and office furniture and fixtures Equipment and machinery at Weldona extraction facility $ 1,151,263 — Golden, Colorado industrial hemp laboratory - equipment 39,944 34,651 Golden, Colorado administrative offices: Furniture and fixtures 49,282 21,668 Leasehold improvements 209,796 2,000 Transportation equipment 234,964 81,667 Remote laboratory equipment 99,220 99,220 Farm Equipment 436,492 — $ 2,220,961 239,206 Accumulated amortization and depreciation (298,465 ) (39,385 ) $ 1,922,496 $ 199,821

PURCHASE OF PRANA THERAPUETIC_2

PURCHASE OF PRANA THERAPUETICS, INC. (Tables)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Schedule of allocation of purchase price	The purchase price for PTI was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. The allocation of the purchase price was, as follows: September 30, 2018 Patents $ 52,596 Net assets 522,761 Goodwill 4,495,143 Total $ 5,070,500

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	9 Months Ended
	Sep. 30, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	Our deferred revenue consists of: September 30, December 31, 2018 2017 Current portion $ 68,750 $ 180,000 Long term portion — 23,750 Deferred revenue $ 68,750 $ 203,750

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2018
Convertible Notes Payable
Schedule of Convertible Promissory Notes Issued	The following table summarizes our convertible promissory notes outstanding as of September 30, 2018 and December 31, 2017: Issue Holder Security Maturity Interest Base September 30, December 31, 6-04-18 Tangiers Global Unsecured 12-04-18 5% Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holder’s election to convert $ 288,750 $ — Less unamortized Discount (4,889 ) — $ 283,861 $ —

NOTES PAYABLE FOR ADVANCES FR_2

NOTES PAYABLE FOR ADVANCES FROM AND PRIOR WAGES PAYABLE TO OFFICERS AND DIRECTORS (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Notes payable to and advance from officers and directors	Notes payable, including accrued interest payable, to and advance from officers and directors consisted of the following: September 30, December 31, 2018 2017 Notes payable to Earnie Blackmon, an officer and director $ 816,195 $ 246,459 Note payable to Tony Verzura, an officer and director 159,833 14,889 Note payable to Chadwick Ruby, an officer and director 149,864 — $ 1,125,892 $ 261,348

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of share warrants outstanding	The following table summarizes our warrants outstanding as of September 30, 2018 and December 31, 2017: September 30, December 31, 2018 2017 Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Warrants outstanding, beginning of period 1,209,025 $ 0.21 $ 1,551,356 $ 0.18 Warrants issued to consultants 75,006 0.95 132,669 Warrants exercised — (475,000 ) Warrants outstanding, end of period 1,284,031 $ 0.31 1,209,025 $ 0.21 Warrants exercisable, end of period 1,284,031 $ 0.31 1,209,025 $ 0.21
Summary of stock options outstanding	The following table summarizes our stock options outstanding as of both September 30, 2018 and December 31, 2017, respectively: Number of Weighted Weighted Stock options outstanding at January 1, 2017 3,680,000 8.9 $ 0.28 Issued 3,957,500 9.9 0.64 Exercised (1,000,000 ) Expired — Stock options outstanding at December 31, 2017 6,637,500 8.7 $ 0.57 Stock options exercisable at December 31. 2017 6,637,500 8.7 $ 0.57 Stock options outstanding at December 31, 2017 6,637,500 Issued 20,195,000 9.5 $ 0.83 Exercised — Expired — Stock options outstanding at September 30, 2018 26,832,500 9.4 $ 0.75 Stock options exercisable at September 30, 2018 25,080,000 9.5 $ 0.74
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.91 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 1.05 Exercise price $ 1.08 Risk free interest rate 2.8 % Expected term (years) 5-10 Expected volatility 197 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.59 per option utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.71 Exercise price $ 0.95 Risk free interest rate 2.68 - 2.79 % Expected term (years) 5 Expected volatility 210% - 214 % Expected dividends 0 %
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	666,667 warrants issued during the year ended December 31, 2017 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 % 75,006 warrants issued during the nine months ended September 30, 2018 were valued utilizing the Black Scholes option pricing model and the following range of assumptions on the date of valuation: Stock price $ 0.16 - $2.18 Exercise price $ 0.18 Risk free interest rate 1.01% - 1.37 % Expected term (years) 5 Expected volatility 322% - 504 % Expected dividends 0 %

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	We recognize share-based compensation expense in cost of revenues, sales and marketing expenses, research and development expenses, general and administrative expenses, and other income and expenses, based on the fair value of common shares issued for services. In addition, we accrue share-based compensation expense for estimated share-based awards earned during the nine months ended September 30, 2018 and 2017, Stock Incentive Plans. Share-based compensation expense for the three months and nine months ended September 30, 2018 and 2017 is, as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Options granted to officers, directors and employees $ 179,018 $ — $ 14,689,497 $ 1,812,456 Common stock issued for accounts payable and accrued expenses — 22,949 — 117,509 Options granted for services — — — — Warrants and options issued for consulting services 25,002 — 76,322 16,379 Common stock issued for services 77,164 68,984 238,637 170,958 Common stock issued as compensation to employees 42,600 — 233,700 — $ 323,784 $ 91,933 $ 15,238,156 $ 2,117,302

SIGNIFICANT CUSTOMER INFORMAT_2

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Tables)	9 Months Ended
	Sep. 30, 2018
Risks and Uncertainties [Abstract]
Schedule of significant concentrations risk	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Nine Months Ended September 30, 2018 2017 Customer A 14 % 82 % Customer B 14 % 17 % Customer C 9 % 1 % Percentage of Accounts Receivable: As of September 30, 2018 2017 Customer D 81 % 0 % Customer E 18 % 0 % Customer F 1 % 0 % The following tables show significant concentrations in our expenses and accounts payable for the periods indicated: Percentage of Expenses: Nine Months Ended September 30, 2018 2017 Vendor A 4 % 13 % Vendor B 2 % 6 % Vendor C 2 % 4 % Percentage of Accounts Payable: As of September 30, 2018 2017 Vendor D 21 % 72 % Vendor E 12 % 13 % Vendor F 10 % 6 %

BUSINESS ORGANIZATION AND NAT_2

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2014	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 26, 2014
Amount of payable owed to former officer and director, exchanged for assets sold		$ 15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period							41,690,000
Common stock, shares outstanding			74,180,490		62,862,066		43,620,000
Business Development			$ 2,800,000
Prana [Member]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Prana [Member] | Subscription Agreement [Member]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000		$ 50,000	$ 50,000	$ 50,000	$ 50,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Allowance for doubtful accounts	$ 0		$ 0
Bad debt expense, included in general and administrative expenses	0
Goodwill	4,838,603		$ 4,838,603
Purchase Price Allocation	5,070,500
Excess of purchase price over fair values of net tangible assets and intangible assets recorded as goodwill	$ 4,731,729
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Estimated useful life	10 years
Equity Method Investments, Percentage	50.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Estimated useful life	15 years
Equity Method Investments, Percentage	20.00%
Patents [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
PTI [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	95.00%
Goodwill	$ 4,495,143
Purchase Price Allocation	$ 5,070,500
CRD [Member]
Property, Plant and Equipment [Line Items]
Equity Method Investments, Percentage	50.00%
Goodwill	$ 106,874

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	26,351,530	8,004,112	26,364,031	8,004,112
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	1,271,530	1,424,112	1,284,031	1,424,112
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	25,080,000	6,580,000	25,080,000	6,580,000

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
GOING CONCERN [Abstract]
Net loss	$ 2,982,403	$ 653,706	$ 21,070,952	$ 3,729,687
Net cash used in operating activities			3,230,108	$ 1,001,166
Accumulated deficit	$ 36,218,959		$ 36,218,959		$ 15,269,845

DUE FROM RELATED PARTIES (Sched

DUE FROM RELATED PARTIES (Schedule of Amounts Due from Related Parties) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Total due from related parties	$ 103,402
Advesa, Inc. [Member]
Related Party Transaction [Line Items]
Total due from related parties	44,402
NutriMed, LLC [Member]
Related Party Transaction [Line Items]
Total due from related parties	$ 59,000

OPERATING LEASES (Narrative) (D

OPERATING LEASES (Narrative) (Details)	Sep. 01, 2018USD ($)ft²	Oct. 01, 2017ft²	Aug. 01, 2017ft²	Sep. 30, 2018USD ($)a	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
CRD [Member]
Operating Leased Assets [Line Items]
Equity Method Investments, Percentage				50.00%
Lease amount from father of directors and members				$ 1
Industrial Hemp Laboratory - Golden, Colorado [Member]
Operating Leased Assets [Line Items]
Area of lease | ft²			9,882
Maturity date			Jul. 31, 2020
Industrial Hemp Laboratory - Golden, Colorado [Member] | Subsequent Event [Member]
Operating Leased Assets [Line Items]
Basic rent per month					$ 3,800	$ 3,500	$ 3,302
Colorado Extraction Facility [Member]
Operating Leased Assets [Line Items]
Area of lease | ft²	14,300	40,000
Maturity date	Aug. 31, 2023	Sep. 30, 2018
Basic rent per month	$ 12,596			$ 7,500
Jamaica Cultivation and Extraction Facility [Member]
Operating Leased Assets [Line Items]
Area of lease | a				28

OPERATING LEASES (Schedule of F

OPERATING LEASES (Schedule of Future Minimum Payament) (Details)	Sep. 30, 2018USD ($)
Leases [Abstract]
2,019	$ 283,753
2,020	279,150
2,021	241,153
2,021	241,153
2,022	$ 158,365

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 2,511,396	$ 15,000
Work-in-process	49,735
Finished goods	101,320	28,200
Inventory	$ 2,662,451	$ 43,200

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation and amortization			$ 264,445	$ 26,299
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 106,567	$ 18,449	$ 259,108	$ 25,106

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	$ 961,527	$ 832,697
Extraction facility, laboratory equipment, and office furniture and fixtures	2,220,961	239,206
Accumulated amortization and depreciation	(298,465)	(39,385)
Cultivation facility and laboratory equipment and Office furniture and fixtures	1,922,496	199,821
Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility		647,947
Equipment [Member] | Mead, Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	775,828
Leasehold Improvements - Laboratory [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	75,000	75,000
Leasehold Improvements - Cultivation [Member] | Jamaica Cultivation and Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Cost of construction in process - extraction facility	110,699	109,750
Equipment and machinery at Weldona extraction facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	1,151,263
Golden, Colorado Industrial Hemp Laboratory - Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	39,944	34,651
Furniture and Fixtures [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	49,282	21,668
Leasehold Improvements [Member] | Colorado Administrative Offices [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	209,796	2,000
Transportation Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	234,964	81,667
Remote Laboratory Equipment [Member] | Colorado Extraction Facility [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	99,220	99,220
Farm Equipment [Member]
Property, Plant and Equipment [Line Items]
Extraction facility, laboratory equipment, and office furniture and fixtures	$ 436,492

PURCHASE OF PRANA THERAPUETIC_3

PURCHASE OF PRANA THERAPUETICS, INC. (Narrative) (Details) - Prana [Member] - USD ($)	Jul. 14, 2017	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Business Acquisition [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Shares issued in acquisition	400,000
Shares issued in acquisition, value	$ 200,000
Subscription Agreement [Member]
Business Acquisition [Line Items]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000

PURCHASE OF PRANA THERAPUETIC_4

PURCHASE OF PRANA THERAPUETICS, INC. (Schedule of Purchase Price Allocation) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 4,838,603	$ 4,838,603
Purchase Price Allocation	5,070,500
PTI [Member]
Business Acquisition [Line Items]
Patents	52,596
Net assets	522,761
Goodwill	4,495,143
Purchase Price Allocation	$ 5,070,500

GRANTED PATENTS, NET (Details)

GRANTED PATENTS, NET (Details) - Patents [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Aug. 15, 2017
Finite-Lived Intangible Assets [Line Items]
Estimated useful live			15 years
Amortization expense	$ 1,779	$ 0	$ 5,337	$ 0
Accumulated amortization	$ 8,016		$ 8,016		$ 2,679
Research, legal fees						$ 142,317

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details)	9 Months Ended
	Sep. 30, 2018
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

INSTALLMENT LOANS PAYABLE (Deta

INSTALLMENT LOANS PAYABLE (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Installment loan payable	$ 64,278	$ 46,667
Installment One [Member]
Short-term Debt [Line Items]
Installment loan monthly payment	955
Monthly payments being made to pay off loan in six months	$ 6,955
Term period	48 months
Installment Two [Member]
Short-term Debt [Line Items]
Installment loan monthly payment	$ 2,160
Monthly payments being made to pay off loan in six months	$ 6,500
Term period	36 months
48 Month Installment [Member]
Short-term Debt [Line Items]
Installment loan payable	$ 0	46,667
36 Month Installment [Member]
Short-term Debt [Line Items]
Installment loan payable	$ 68,750	$ 46,667

DEFERRED REVENUE (Narrative) (D

DEFERRED REVENUE (Narrative) (Details) - USD ($)	Sep. 09, 2014	Dec. 31, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2019	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Deferred revenue			$ 68,750			$ 203,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month			15,000
Total deferred revenue recognized		$ 150,000	90,000	$ 90,000
Deferred revenue			$ 68,750
WeedMD RX Inc. (''WMD'') [Member] | Subsequent Event [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue					$ 68,750

DEFERRED REVENUE (Schedule of d

DEFERRED REVENUE (Schedule of deferred revenue) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Current portion	$ 68,750	$ 180,000
Long term portion		23,750
Deferred revenue	$ 68,750	$ 203,750

CONVERTIBLE NOTES PAYABLE (Narr

CONVERTIBLE NOTES PAYABLE (Narrative) (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)shares	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
CONVERTIBLE NOTE PAYABLE [Abstract]
Amortization of debt discount	$ 22,042	$ 22,042	$ 34,453
Amount of convertible note	$ 600,000
Issaunce of common stock | shares	1,956,522
Gain (loss) on conversion of convertible note	$ 600,000	$ 496,023

CONVERTIBLE NOTES PAYABLE (Sche

CONVERTIBLE NOTES PAYABLE (Schedule of Convertible Promissory Notes Issued) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total principal outstanding
Less unamortized discount	$ (4,889)
Total of outstanding amount	$ 283,861
Tangiers Investment Group [Member] | 2016 Convertible Notes [Member]
Debt Instrument [Line Items]
Issue Date	Jun. 4, 2018
Holder	Tangiers Global
Security	Unsecured
Maturity Date	Dec. 4, 2018
Base Conversion Rate	Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holder’s election to convert</p>" id="sjs-B13">&lt;p style="margin: 0">Upon default, Holder may convert all or a part of the note at a rate of 70% of the average of the two lowest trading prices during 15-day period prior to Holder&#8217;s election to convert&lt;/p>
Tangiers Investment Group [Member] | 2018 Convertible Notes [Member]
Debt Instrument [Line Items]
Interest Rate	5.00%
Total principal outstanding	$ 288,750

NOTES PAYABLE FOR ADVANCES FR_3

NOTES PAYABLE FOR ADVANCES FROM AND PRIOR WAGES PAYABLE TO OFFICERS AND DIRECTORS (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Jul. 02, 2018	Dec. 31, 2017	Dec. 30, 2016	Apr. 06, 2016	Oct. 12, 2015
Related Party Transaction [Line Items]
Principal balance increase				$ 57,500
Debt repayment terms	If the loans are repaid on or before September 30, 2016, the principal amount, which is being repaid, will increase by 10%. If the loans are repaid after September 30, 2016, the principal amount, which is being repaid will increase by 15%.
Notes payable to and advances from officers and directors	$ 554,143
Notes payable	310,408
Accrued wages payable to officers and directors [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	1,125,892		$ 261,347
Earnie Blackmon [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	816,195		246,458
Tony Verzura [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 25,000
Tony Verzura [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	159,833		14,889
Chadwick Ruby [Member] | Notes Payable Other Payables [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party	$ 149,864
Ernest Blackmon [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 25,000
Debt instrument, interest rate		15.00%
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Convertible note payable, related party						$ 102,000
JSJ Investments Inc. [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate				12.00%
Messrs. Verzura and Ruby [Member]
Related Party Transaction [Line Items]
Debt instrument, interest rate		12.50%

ARBITRATION AND LITIGATION RE_2

ARBITRATION AND LITIGATION RESERVE (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Loss Contingency [Abstract]
Arbitration settlement reserve	$ 650,000
Proceeds from proposed joint venture that was never formed	650,000
Amount of refund	650,000
Lawsuit damages claims	$ 16,500,000

STOCKHOLDERS' EQUITY (Narrative

STOCKHOLDERS' EQUITY (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Jul. 18, 2017	Sep. 30, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Aggregate intrinsic value of warrants outstanding and exercisable		$ 75,006
Warrant issued		75,006	132,669
Warrants [Member]
Class of Stock [Line Items]
Warrant issued		0	666,667
Weighted-average remaining contractual life for stock options outstanding and exercisable		3 years 7 months 17 days
Preferred Class A [Member] | Officer and Director [Member]
Class of Stock [Line Items]
Share issued	2,000
Proceeds from shares issued	$ 2,200

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock Issued For Services, Warrants) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Shares
Warrants outstanding, beginning of period	1,209,025	1,551,356
Warrants issued to consultants	75,006	132,669
Warrants exercised		(475,000)
Warrants outstanding, end of period	1,284,031	1,209,025
Warrants exercisable, end of period	1,284,031	1,209,025
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)	$ 0.21	$ 0.18
Warrants issued to consultants (in dollars per share)	0.95
Warrants outstanding, end of period (in dollars per share)	0.31	0.21
Warrants exercisable, end of period (in dollars per share)	$ 0.31	$ 0.21

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	1 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2018	Sep. 30, 2018	Dec. 31, 2017
Warrants [Member]
Class of Stock [Line Items]
Exercise price (in dollars per share)		$ 0.18	$ 0.18
Expected term (years)		5 years	5 years
Expected dividends (as a percent)		0.00%	0.00%
Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)		$ 0.16	$ 0.16
Risk free interest rate (as a percent)		1.01%	1.01%
Expected volatility (as a percent)		322.00%	322.00%
Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)		$ 2.18	$ 2.18
Risk free interest rate (as a percent)		1.37%	1.37%
Expected volatility (as a percent)		504.00%	504.00%
Stock Options [Member]
Class of Stock [Line Items]
Stock price (in dollars per share)	$ 1.05	$ 0.71
Exercise price (in dollars per share)	$ 1.08	$ 0.95
Risk free interest rate (as a percent)	2.80%
Expected term (years)		5 years
Expected volatility (as a percent)	197.00%
Expected dividends (as a percent)	0.00%	0.00%
Stock Options [Member] | Minimum [Member]
Class of Stock [Line Items]
Risk free interest rate (as a percent)		2.68%
Expected term (years)	5 years
Expected volatility (as a percent)		210.00%
Stock Options [Member] | Maximum [Member]
Class of Stock [Line Items]
Risk free interest rate (as a percent)		2.79%
Expected term (years)	10 years
Expected volatility (as a percent)		214.00%

STOCKHOLDERS' EQUITY (Schedul_2

STOCKHOLDERS' EQUITY (Schedule of stock option activity) (Details) - Stock Options [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Stock options outstanding, beginning of period	6,637,500	3,680,000	600,000
Issued	20,195,000	3,957,500
Exercised		(1,000,000)
Expired
Stock options outstanding, end of period	26,832,500	6,637,500	3,680,000
Stock options outstanding, end of period	25,080,000	6,637,500
Weighted Average Exercise Price
Stock options outstanding, beginning of period	$ 0.57	$ 0.28	$ 0.70
Issued	0.83	0.64
Stock options outstanding, end of period	0.75	0.57	$ 0.28
Stock options exercisable, end of period	$ 0.74	$ 0.57
Weighted Average Remaining Life (Years)
Stock options outstanding, beginning of period	9 years 6 months	9 years 10 months 25 days	8 years 10 months 25 days
Stock options Issued, end of period	9 years 4 months 24 days	8 years 8 months 12 days
Stock options exercisable, end of period	9 years 6 months	8 years 8 months 12 days

STOCKHOLDERS' EQUITY (Stock Opt

STOCKHOLDERS' EQUITY (Stock Option Activity) (Narrative) (Details) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 17, 2018	Jul. 25, 2018	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017	Jun. 29, 2018	Jun. 25, 2018	Feb. 28, 2018
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options			$ 14,195,000	$ 14,195,000
Fair value of options			6,146,000	6,146,000		9,711,400
Weighted-average remaining contractual life for stock options outstanding and exercisable				9 years 6 months	8 years 8 months 12 days
Aggregate intrinsic value of options outstanding and exercisable			$ 1	$ 1
Option vested			5,125,000	5,125,000
Stock options compensation			$ 9,104,999	$ 5,584,498
Total price to exercise all outstanding stock options			$ 10,259,575	$ 10,259,575
Stock options to purchase common stock		6,000,000
Stock Options [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	600,000
Stock Options [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	2,900,000
Stock Options [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	57,500
Stock Options [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	1,000,000
Stock Options [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	6,000,000
Stock Options [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options to purchase common stock	14,195,000
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price						$ .705	$ 1.08
Stock Options [Member] | Minimum [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.70
Stock Options [Member] | Minimum [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.56
Stock Options [Member] | Minimum [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.92
Stock Options [Member] | Minimum [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.875
Stock Options [Member] | Minimum [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	.058
Stock Options [Member] | Minimum [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.58
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price						$ 0.58	$ 0.58
Stock Options [Member] | Maximum [Member] | Granted on January 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on January 12, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on July 27, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on December 8, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on March 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	0.43
Stock Options [Member] | Maximum [Member] | Granted on June 29, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 0.43
Stock Options [Member] | Vesting through December 31, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vested			875,000	875,000
Stock Options [Member] | Vesting quarterly through July 1, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vested			945,000	945,000
2017 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options								$ 6,000,000
Stock Incentive Plan 2018 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awarded stock options						$ 14,195,000
Option vested			13,250,000	13,250,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options granted to officers, directors and employees	$ 179,018		$ 14,689,497	$ 1,812,456
Common stock issued for accounts payable and accrued expenses		22,949		117,509
Options granted for services
Warrants and options issued for consulting services	25,002		76,322	16,379
Common stock issued for services	77,164	68,984	238,637	170,958
Common stock issued as compensation to employees	42,600		233,700
Share-based compensation	$ 323,784	$ 91,933	$ 15,238,156	$ 2,117,302

SIGNIFICANT CUSTOMER INFORMAT_3

SIGNIFICANT CUSTOMER INFORMATION AND ECONOMIC DEPENDENCY (Schedule of concentration of risk) (Details)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	82.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	17.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	1.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%	0.00%
Accounts Receivable [Member] | Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18.00%	0.00%
Accounts Receivable [Member] | Customer F [Member]
Concentration Risk [Line Items]
Concentration risk percentage	1.00%	0.00%
Expenses [Member] | Vendor A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	4.00%	13.00%
Expenses [Member] | Vendor B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	2.00%	6.00%
Expenses [Member] | Vendor C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	2.00%	4.00%
Accounts Payable [Member] | Vendor D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21.00%	72.00%
Accounts Payable [Member] | Vendor E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	12.00%	13.00%
Accounts Payable [Member] | Vendor F [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10.00%	6.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)	Oct. 02, 2018	Aug. 03, 2018	Sep. 30, 2018	Jan. 19, 2018	Oct. 31, 2017
Long-term Purchase Commitment [Line Items]
Minimum amount draw down at one time			$ 5,000
Percentage of number of common shares			400.00%
Maximum amount draw down at one time			$ 1,000,000
Percentage of trading price			85.00%
Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Farm lease acreage			$ 1,000
Price for harvested crop per pound			$ 2
Installment One [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable			Nov. 15, 2018
Installment Two [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable			Dec. 31, 2018
Installment Three [Member] | Industrial Hemp Crop Under Cultivation [Member]
Long-term Purchase Commitment [Line Items]
Date for rent payable			Feb. 15, 2019
Tangiers Global, LLC [Member]
Long-term Purchase Commitment [Line Items]
Line of Credit agreement			$ 5,390,049	$ 10,000,000
Sale of stock			8,655,711
Clinical Trial Agreement [Member] | Installment One [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement			$ 50,000
Clinical Trial Agreement [Member] | Installment Two [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement			51,182
Clinical Trial Agreement [Member] | Installment Three [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement			51,182
Clinical Trial Agreement [Member] | Installment Four [Member]
Long-term Purchase Commitment [Line Items]
Payment made for clinical trial agreement			$ 51,182
IND [Member]
Long-term Purchase Commitment [Line Items]
Committed expense		$ 300,000
PTI [Member]
Long-term Purchase Commitment [Line Items]
Percentage of ownership		95.00%
Prana [Member]
Long-term Purchase Commitment [Line Items]
Total commitment upon execution of research agreement					$ 303,544
Commitment owed in June 2018					$ 75,886
Industrial hemp biomass [Member]
Long-term Purchase Commitment [Line Items]
Business consideration Transferred	$ 1,152,000

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Nov. 08, 2018	Nov. 09, 2018	Sep. 30, 2018
Subsequent Event [Line Items]
Amount of convertible note			$ 600,000
Subsequent Event [Member] | Tangiers Global, LLC [Member]
Subsequent Event [Line Items]
Line of Credit agreement		$ 701,400
Sale of stock		1,630,051
Amount of convertible note	$ 1,500,000
Percentage of convertible note	70.00%